They compared these results with the use of O-hydroxyacetamide SA-57 (Figure S1) a dual FAAH/MAGL inhibitor (IC50 mFAAH = 1.0 nM, IC50 mMAGL = 410 nM) developed by Sanofi-Aventis, which represented a prototype of innovative compounds as pharmacological tools for CNS disorders [159,164]. The gene discussed is FAAH; the disease is central nervous system disorder.